anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a powder cosmetic which can be readily transferred to a puff and is excellent in impression at use (smoothness, fitting to the skin, etc.) and impact resistance, and a method for producing the same.  <P>SOLUTION: The powder cosmetic contains 75-95 mass% powder component and 5-25 mass% oily component as a binder, provided that the cosmetic contains 0.5-20.0 mass% spherical powder, based on the total mass of the cosmetic, as a part of the powder component. Here, a portion or all of the spherical powder exists in the cosmetic in a state wherein the entire powder surface is not covered by the oily component. A kneading torque value, determined by a specific testing method using the oily component and the powder component excluding the spherical powder, is 0.015-0.05 kg.m.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Because beta-blocker withdrawal has been associated with an increased risk of MI and chest pain, patients already on beta-blockers should generally continue treatment throughout the perioperative period. If BYSTOLIC is to be continued perioperatively, monitor patients closely when anesthetic agents which depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used. If β-blocking therapy is withdrawn prior to major surgery, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. 

The β-blocking effects of BYSTOLIC can be reversed by β-agonists, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe hypotension. Additionally, difficulty in restarting and maintaining the heartbeat has been reported with β-blockers.
FIELD: medicine, oncology. SUBSTANCE: invention proposes novel method of regional chemotherapy by intravascular administration of medicinal agents that involves installing arterio-arterial shunt by long 15-20 cm, not above, and administration of direct anticoagulating agent is excluded from chemotherapy scheme. Method allows to achieve tumor reduction without conventional complications as necrosis of vascular wall, scar complications and shunt thrombosis. The decrease of life quality of patients has not been observed. EFFECT: improved method of chemotherapy. 3 ex
Sunitinib malate can cause QT interval prolongation in a dose-dependent manner, which may lead to an increased risk for ventricular arrhythmias including Torsade de Pointes. Torsade de Pointes was observed in <0.1% of patients.

Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. Consider periodic monitoring of electrocardiograms and electrolytes (i.e., magnesium, potassium) during treatment with sunitinib malate.

Monitor QT interval more frequently when sunitinib malate is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. Consider dose reducing sunitinib malate [see Dosage and Administration ( 2.5), Drug Interactions ( 7.2)] .
D-glyceric acid has been found to enhance alcohol metabolism and thereby prevent adverse effects of alcohol consumption. D-glyceric acid is administered concurrently with alcohol, to accelerate the elimination of the alcohol from the body. D-glyceric acid is converted into D-glyceraldehyde and further into glycerol in reactions catalysed by NADH-aldehyde dehydrogenase and NADH-alcohol dehydrogenase complexes, which are produced in excess during alcohol oxidation, in the cells of alcohol-metabolising tissues. In these reactions, the NADH complexes become NAD-aldehyde dehydrogenase and NAD- alcohol dehydrogenase complexes. These complexes which in turn accelerate the oxidation of alcohol, which is paralleled by enhancement of acetaldehyde oxidation to metabolically harmless acetic acid. D-glyceric acid or its salt or ester is used for the manufacture of a pharmaceutical preparation for enhancing the metabolism of alcohol. A method of enhancing the metabolism of alcohol in a subject by administering said compounds an effective amount of D-glyceric acid or its salt or ester is disclosed. An oral or parenteral pharmaceutical preparation comprising said compounds is also disclosed.
BACKGROUND: The outcome of poor grade subarachnoid hemorrhage (SAH) is dismal. Some of these patients need cerebrospinal fluid (CSF) drainage procedure for the hydrocephalus and intraventricular hemorrhage (IVH) which may precipitate rebleeding. However, aneurysmal rebleed following CSF drainage procedure is controversial.
OBJECTIVE: Our study aimed at analyzing the effect of CSF drainage procedure on aneurysmal rebleeding.
MATERIAL AND METHODS: We retrospectively analyzed the records of all the consecutive patients diagnosed with poor grade aneurysmal SAH over three year period. Patients initially requiring either external ventricular drainage (EVD) or lumbar drain (LD) were included in the study group, and the rest (not requiring drainage) were included in the control group. Rebleeding was confirmed on computed tomography. The factors affecting rebleeding were analyzed.
RESULTS: Overall 194 patients with poor grade SAH were enrolled in the study (91 males: 103 females; mean age: 50.6 years). The study group had 91 patients (83 EVD and 8 LD) while 103 patients were in the control group. Posterior circulation aneurysms, poor grade SAH, hydrocephalus, and IVH were more common in the study group P < 0.001. The rebleeding rate was 7.6% in the study group and 8.7% in the control group. On univariate analysis size >1 cm, multiplicity, multilobularity, vasospasm, and CSF drainage were significant risk factors for rebleeding (P < 0.001). On multivariate analysis aneurysm size >1 cm, CSF overdrainage >250 ml/day were significantly associated with risk of rebleeding.
CONCLUSION: Ventricular drainage is essential to relieve acute hydrocephalus and drain IVH in SAH and we found no significant association between CSF drainage and rebleeding. However, rapid overdrainage of CSF can lead to aneurysm rupture, hence controlled controlled CSF drainage should be undertaken.
A method for electrostatic coating of medical devices such as stents and balloons is described. The method includes applying a composition to a polymeric component of a medical device which has little or no conductivity. The polymeric component could be a material from which the body or a strut of the stent is made or could be a polymeric coating pre-applied on the stent. The polymeric component could be the balloon wall. A charge can then be applied to the polymeric component or the polymeric component can be grounded. Charged particles of drugs, polymers, biobeneficial agents, or any combination of these can then be electrostatically deposited on the medical device or the coating on the medical device. One example of the composition is iodine, iodine, iodide, iodate, a complex or salt thereof which can also impart imaging capabilities to the medical device.
Provided herein are compositions to treat Clostridioid.es difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M. tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown drug resistant to vancomycin. In 2017, Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among hospitalized patients and 5,400 estimated deaths in the United States.
Subjects randomized to the Intervention arm will receive standard of care plus 1 gram of vancomycin powder applied topically to the wound bed before the dressing is applied. Intervention will occur in the emergency room prior to surgical intervention.
PURPOSE:To obtain the subject antibody, having the antibody activity against a specific antigen, excellent in preservation stability and fluidity and readily producible at a low cost by removing an impurity such as a lipid from an egg yolk of a laying hen immunized with the specific antigen. CONSTITUTION:A specific antigen (e.g. Streptococcus.mutans MT8148 microbial cell) is intramuscularly injected to immunize a laying hen once a week and four times in total. Hen's eggs are then collected for 3 months after the final immunization and the egg yolk is separated, homogenized in a homomixer, then sterilized at 63 deg.C for 3min and powdered by a hot-air drying method (inlet temperature: 150 deg.C and outlet temperature: 80 deg.C). The resultant egg yolk powder is subsequently placed in an extraction vessel of a supercritical extractor and brought into contact with carbon dioxide in a supercritical gaseous state under conditions of 40 deg.C and 300kg/cm<2> to remove impurities such as a lipid. Thereby, the objective high-purity specific hen's egg antibody having the antibody activity against a specific antigen is obtained at a high recovery ratio.
A composition for topical application to the skin which is used for lightening of skin and for eliminating or lightening dark spots on the skin is described. The composition is in the form of solutions, lotions, gels, creams or sprays and contains a combination of a flavonoid and ascorbic acid or a derivative thereof. This mixture exerts a synergistic effect. This composition can furthermore contain an agent to suppress the tyrosinase activity plus tocopherol or a derivative thereof. The compositions which contain a combination of ascorbic acid or a derivative thereof and a flavonoid display a potent effect. This effect is further enhanced by addition of a composition to reduce the tyrosinase activity by copper chelate formation, such as kojic acid, and/or by addition of a tocopherol or a derivative thereof.
Patients with chronic kidney disease (CKD), especially those who are on dialysis have a high prevalence of cardiovascular mortality and, among the risk factors include inflammation and oxidative stress. Recently this scenario, beyond those alterations found in these patients, it has been suggested that the balance of the intestinal flora in these patients might be a new factor of cardiovascular risk. Some treatment strategies have been studied in order to modulate the gut microbiota as the use of pre, pro or synbiotics. Although few studies, supplementation with prebiotics has been recommended. However, the use of resistant starch as a source of prebiotic for modulation of the intestinal flora in these patients has not yet been evaluated, but the study of Prof. Vaziri the University of California Irvine, USA, with nephrectomized rats showed that the resistant starch was able to attenuating the progression of failure of renal function, inflammation and oxidative stress and minimize the abnormalities of intestinal epithelial barrier. The objective of this study is to assess whether supplementation with resistant starch from the rice-flour coffee developed by EMBRAPA, as well as from an already industrialized product (Hi-Maize of Ingredion®) could modulate the intestinal microbiota of patients with CKD ( both patients under conservative treatment, such as dialysis treatment), as well as exerting a beneficial effect with respect to reducing levels of inflammatory markers of oxidative stress, uremic toxins and in addition, markers of cardiovascular disease.
Early and progressive dysfunctions of the dopaminergic system from the Ventral Tegmental Area (VTA) have been described in Alzheimer's Disease (AD). During the long pre-symptomatic phase, alterations in the function of Parvalbumin interneurons (PV-INs) are also observed, resulting in cortical hyperexcitability represented by subclinical epilepsy and aberrant gamma-oscillations. However, it is unknown whether the dopaminergic deficits contribute to brain hyperexcitability in AD. Here, using the Tg2576 mouse model of AD, we prove that reduced hippocampal dopaminergic innervation, due to VTA dopamine neuron degeneration, impairs PV-IN firing and gamma-waves, weakens the inhibition of pyramidal neurons and induces hippocampal hyperexcitability via lower D2-receptor-mediated activation of the CREB-pathway. These alterations coincide with reduced PV-IN numbers and Perineuronal Net density. Importantly, L-DOPA and the selective D2-receptor agonist quinpirole rescue p-CREB levels and improve the PV-IN-mediated inhibition, thus reducing hyperexcitability. Moreover, similarly to quinpirole, sumanirole - another D2-receptor agonist and a known anticonvulsant - not only increases p-CREB levels in PV-INs but also restores gamma-oscillations in Tg2576 mice. Conversely, blocking the dopaminergic transmission with sulpiride (a D2-like receptor antagonist) in WT mice reduces p-CREB levels in PV-INs, mimicking what occurs in Tg2576. Overall, these findings support the hypothesis that the VTA dopaminergic system integrity plays a key role in hippocampal PV-IN function and survival, disclosing a relevant contribution of the reduced dopaminergic tone to aberrant gamma-waves, hippocampal hyperexcitability and epileptiform activity in early AD.
Background: In vitro studies suggest that low levels of amplitude-modulated electromagnetic fields may modify cell growth. We have identified specific frequencies that may block cancer cell growth. We have developed a portable and programmable device delivering low levels of amplitude-modulated electromagnetic fields. The device is connected to a spoon-like coupler, which is placed in the patient's mouth during treatment.

Methods: We will conducted a feasibility study consisting of three daily treatments. All patients with advanced solid tumors and measurable disease will be eligible, irrespective of prior treatments. Patients will be assessed with laboratory exams (complete blood count, comprehensive profile, tumor markers), imaging studies every other month for the first six months, every third month thereafter.
The study treatment is radiotherapy. Different doses of radiotherapy will be given to patients. The first group of patients will receive the lowest dose (dose level 1) (this is the dose delivered to patients as standard of care). If the treatment does not cause serious side effects, it will be given to the next group of patients enrolled at a higher dose (dose level 2) (this is called 'dose escalation'). If this higher dose of treatment does not cause serious side effects, the next group of patients will receive a higher dose (dose level 3). The doses will continue to increase for every group of patients, as long as no serious side effects occur. If this happens, the study is halted. Once the optimum dose level has been reached, a larger cohort of patients will all receive this dose.

Phase I: A 3+3 dose escalation design is proposed to determine the maximum tolerated dose (MTD) defined by the number of radiotherapy-related ≥ Grade 3 acute toxicities assessed up to 4 weeks post RT. Three cohorts of between 3 and 6 patients at each dose level will be accrued in order to establish the MTD (minimum of 6, maximum of 18 patients). The MTD defined in Phase I will be the dose which will be used in Phase II of the trial. Phase II: 49 patients: Once the MTD is established, patients will continue to be recruited at that dose level up to a total of 49 patients.
Estimating progression-free survival (PFS) and overall survival superiority during clinical trials of multiple myeloma (MM) has become increasingly challenging as novel therapeutics have improved patient outcomes. Thus, it is imperative to identify earlier end point surrogates that are predictive of long-term clinical benefit. Minimal residual disease (MRD)-negativity is a common intermediate end point that has shown prognostic value for clinical benefit in MM. This meta-analysis was based on the US Food and Drug Administration guidance for considerations for a meta-analysis of MRD as a clinical end point and evaluates MRD-negativity as an early end point reasonably likely to predict long-term clinical benefit. Eligible studies were phase 2 or 3 randomized controlled clinical trials measuring MRD-negativity as an end point in patients with MM, with follow-up of ≥6 months following an a priori-defined time point of 12 ± 3 months after randomization. Eight newly diagnosed MM studies evaluating 4907 patients were included. Trial-level associations between MRD-negativity and PFS were R2WLSiv, 0.67 (95% confidence interval [CI], 0.43-0.91) and R2copula 0.84 (0.64 to >0.99) at the 12-month time point. The individual-level association between 12-month MRD-negativity and PFS resulted in a global odds ratio (OR) of 4.02 (95% CI, 2.57-5.46). For relapse/refractory MM, there were 4 studies included, and the individual-level association between 12-month MRD-negativity and PFS resulted in a global OR of 7.67 (4.24-11.10). A clinical trial demonstrating a treatment effect on MRD is reasonably likely to eventually demonstrate a treatment effect on PFS, suggesting that MRD may be an early clinical end point reasonably likely to predict clinical benefit in MM, that may be used to support accelerated approval and thereby, expedite the availability of new drugs to patients with MM.
Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
Composition and method for processing prolamin-containing feed source into a low-vitreous gelatinous feedstuff. The feedstuff is fed to ruminant animals for the purpose of potentiating either milk production and/or conception. The feed source can be corn and the ruminant animal can be a bovine, and might be a cow. The method includes processing, by extrusion, a prolamin-containing feed source having a starch-protein matrix within which the included protein is composed of at least 3% percent prolamin. This processing produces a hydrophilic gelatinous feedstuff that has starch and protein content. The hydrophilic low-vitreous gelatinous feedstuff is fed to a ruminant animal. A rumen-retained portion of the fed feedstuff is retained within the rumen of the animal for at least a twenty-four hour period, and during the first twenty-four hours of that period, at least seventy-five percent of the starch content of the rumen-retained portion of the fed feedstuff is digested.
PURPOSE: To obtain an emulsion having excellent effects on treatment of the skin in cosmetic and dermatological fields by contg. retinol, an oil phase, water phase and an agent for emulsifying the aq. phase in the oil phase, where the oil phase contains at least one org. solvent for dissolving retinol, and the aq. phase is basic. CONSTITUTION: In a water-in-oil emulsion contg. retinol, an oil phase, an aq. phase and an agent for emulsifying the aq. phase in the oil phase, the oil phase contains at least one org. solvent for dissolving retinol which is liq. at room temp., and the pH of the aq. phase is basic so as to stabilize the retinol for at least two months. The emulsion 6 is prepared under an inactive atmosphere without oxygen, and under light causing no photochemical reaction. The accommodation apparatus 2 of products is equipped with a distribution apparatus 8 so as not to bring the products in contact with external air, has a wall having impermeability to gases and visible-ultraviolet light, the surface of the wall in contact with the products is made of nonmetal and the accommodation apparatus is equipped with an oxygen capturing apparatus.
Climate change has resulted in an increased demand for Japanese bunching onions (Allium fistulosum L., genomes FF) with drought resistance. A complete set of alien monosomic addition lines of A. fistulosum with extra chromosomes from shallot (A. cepa L. Aggregatum group, AA), represented as FF + 1A-FF + 8A, displays a variety of phenotypes that significantly differ from those of the recipient species. In this study, we investigated the impact of drought stress on abscisic acid (ABA) and its precursor, β-carotene, utilizing this complete set. In addition, we analyzed the expression levels of genes related to ABA biosynthesis, catabolism, and drought stress signal transduction in FF + 1A and FF + 6A, which show characteristic variations in ABA accumulation. A number of unigenes related to ABA were selected through a database using Allium TDB. Under drought conditions, FF + 1A exhibited significantly higher ABA and β-carotene content compared with FF. Additionally, the expression levels of all ABA-related genes in FF + 1A were higher than those in FF. These results indicate that the addition of chromosome 1A from shallot caused the high expression of ABA biosynthesis genes, leading to increased levels of ABA accumulation. Therefore, it is expected that the introduction of alien genes from the shallot will upwardly modify ABA content, which is directly related to stomatal closure, leading to drought stress tolerance in FF.
The experimental arm of Virtual Mom Power is a manualized multi-family group intervention consisting of 10, 90-minute virtual group + 2 individual sessions led by two co-facilitators. The curriculum includes 5 core components: (1) Attachment-Focused Parenting Education; (2) Self-Care; (3) Parenting Practice; (4) Social Support; \& (5) Connection to Resources. Individual sessions combine motivational interviewing with MP core components and focus on identifying goals and barriers. We will work with mothers in individual coaching to problem-solve childcare and privacy during group time. Weekly between-group phone/text check-ins are also a part of the curriculum, used to strengthen connection, build trust, ensure safety, and assess basic needs. Data regarding attendance will be recorded and total dosage examined in treatment effects.
Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
The invention discloses two shRNAs interfering the expression of human IFN-gama genes, which are shown as SEQ ID NO 1 and SEQ ID NO 2. The invention also discloses a lentivirus expression vector which comprises shRNA for interfering the expression of human IFN-gama gene and a nucleotide segment which is shown as SEQ ID NO. 4 and used for coding the chimeric antigen receptor. The invention also discloses a CD19-CAR-T cell for interfering the expression of the human IFN-gama gene, which is a T lymphocyte containing a lentivirus expression vector, or a T lymphocyte integrating shRNA for interfering the expression of the human IFN-gama gene in a chromosome and a nucleotide fragment for coding a chimeric antigen receptor. IFN-gama shRNA is introduced into the CAR-T cell, the IFN-gama shRNA is co-expressed while the CAR is expressed, and the release of the IFN-gama is inhibited from the source through a gene silencing technology, so that the influence of CRS is reduced, and the safety of CAR-T treatment is improved. It can be expected that the compound has important application in preparing medicaments for preventing, treating and assisting in treating malignant tumors.
Conventional physiotherapy treatment will be applied. The duration will be two weekly sessions of about 50 minutes, for 6 weeks.